Potential Ability of Umbilical Cord-Derived Mesenchymal Stem Cells in The Treatment of Premature Ovarian Failure

Samira Mozaffari Khosravi; Saman Seyedabadin; Seyed Hossein  Shahcheraghi; Marzieh Lotfi

doi:10.18502/ssu.v32i2.15381

Samira Mozaffari Khosravi Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Saman Seyedabadin Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Seyed Hossein Shahcheraghi Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Marzieh Lotfi Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

DOI: https://doi.org/10.18502/ssu.v32i2.15381

Keywords: Menopause, Premature, Mesenchymal Stem Cells, Infertility.

Abstract

Introduction: Women of reproductive age may encounter challenges related to infertility or miscarriage, due to conditions such as premature ovarian failure (POF). POF, affecting approximately one percent of women under the age of 40, can lead to infertility. Current data have suggested that utilizing stem cell therapy was the most effective approach for treating POF compared to alternative options. Among the various stem cell types, mesenchymal stem cells derived from the umbilical cord (HUC-MSCs) was a promising choice for treatment due to its features such as relatively low immunogenicity, multipotent, multiple origins, cost-effectiveness, ease of production, and high efficiency.

Conclusion: One of the ways to treat POF is the use of mesenchymal stem cells derived from the umbilical cord, these cells have an extraordinary capacity for repair and regeneration, which helps them in repairing depleted ovaries. The results of this review article indicate that the use of HUC-MSCs can be considered as a potential treatment method in these patients.